For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of Vyndamax and the formulated version represents a significant breakthrough . These groundbreaking therapies preserve the transthyretin protein, slowing its damaging build-up and reducing the burden of the illness. Individuals are now experien